What are the benefits of Trulicity for blood sugar control?
Trulicity, also known as dulaglutide, is a medication used to treat type 2 diabetes [1]. It belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking the action of a natural hormone in the body that helps regulate blood sugar levels [2].
Studies have shown that Trulicity can help lower HbA1c levels, a measure of average blood sugar control over time, in people with type 2 diabetes [3]. In clinical trials, patients taking Trulicity experienced significant reductions in HbA1c levels compared to those taking a placebo [4]. Additionally, Trulicity has been shown to improve glycemic control, reduce the risk of major adverse cardiovascular events, and slow the progression of kidney disease in patients with type 2 diabetes [5].
How does Trulicity work to lower blood sugar?
Trulicity works by enhancing the body's natural response to high blood sugar levels. It binds to GLP-1 receptors in the pancreas, promoting the release of insulin and suppresses the release of glucagon, a hormone that raises blood sugar levels [2]. This helps to lower blood sugar levels and improve insulin sensitivity [6].
Who is eligible for Trulicity treatment?
Trulicity is approved for use in adults with type 2 diabetes, particularly those who have not achieved adequate glycemic control with other medications [7]. However, Trulicity may not be suitable for everyone, particularly those with a history of pancreatitis or a family history of medullary thyroid carcinoma [8].
Side effects and safety considerations
As with any medication, Trulicity can cause side effects, including nausea, vomiting, diarrhea, and injection site reactions [9]. In rare cases, Trulicity may increase the risk of acute kidney injury, pancreatitis, and thyroid C-cell tumors [10].
When does the patent for Trulicity expire?
According to DrugPatentWatch.com, the patent for Trulicity expires in 2033 [11].
References:
[1] Eli Lilly and Company. (2022). Trulicity Prescribing Information.
[2] DrugBank. (2022). Dulaglutide.
[3] Nauck, M. A., et al. (2013). Efficacy and safety of dulaglutide in type 2 diabetes: A phase 3, randomized, double-blind, placebo-controlled trial [Abstract].
[4] Nauck, M. A., et al. (2013). Efficacy and safety of dulaglutide in type 2 diabetes: A 52-week, randomized, double-blind, placebo-controlled trial.
[5] Bergenstal, R. M., et al. (2015). Efficacy and safety of dulaglutide, an glucagon-like peptide-1 receptor agonist, in people with type 2 diabetes.
[6] Nauck, M. A., et al. (2013). DPP-4 inhibitors and GLP-1 receptor agonists: A review of their role in the treatment of type 2 diabetes.
[7] Eli Lilly and Company. (2022). Trulicity Prescribing Information.
[8] Eli Lilly and Company. (2022). Trulicity Prescribing Information.
[9] Eli Lilly and Company. (2022). Trulicity Prescribing Information.
[10] Eli Lilly and Company. (2022). Trulicity Prescribing Information.
[11] DrugPatentWatch.com. (2022). Dulaglutide Patent Expiration Dates.